The Comparability of Bispectral Index and Neurosense During Anesthesia
The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Suresnes, France, 92150
- Dept of Anesthesia, Hôpital Foch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients requiring either intravenous anesthesia or balanced anesthesia (including sevoflurane)
Exclusion Criteria:
- Pregnant women,
- Allergy to propofol, remifentanil, morphine, muscle relaxant, or to a component,
- Hypersensibility to sufentanil, remifentanil or to a derivate of fentanyl,
- History of neurological disorder or central brain lesion, of muscle disease,
- Patient carrying a pacemaker,
- Patients receiving a psychotropic treatment or a morphine agonist-antagonist,
- Alcoholic patients and patients taking opiates,
- Surgery with extracorporeal circulation,
- Surgical position incompatible with an adequate positioning of the probe.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
patients receiving iv anesthesia
|
propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
simultaneous monitoring with Bis and Neurosense
|
|
patients receiving balanced anesthesia
|
simultaneous monitoring with Bis and Neurosense
dosages are adapted according to clinician's judgment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concordance between pairs of Bispectral Index and Neurosense indices during maintenance of anesthesia
Time Frame: at the end of each case
|
Statistical analysis of concordance
|
at the end of each case
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concordance between pairs of Bispectral Index and Neurosense indices during induction and emergence
Time Frame: at the end of each case
|
Statistical analysis of concordance
|
at the end of each case
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Platelet Aggregation Inhibitors
- Analgesics, Opioid
- Narcotics
- Hypnotics and Sedatives
- Anesthetics, Inhalation
- Neuromuscular Agents
- Nicotinic Antagonists
- Neuromuscular Nondepolarizing Agents
- Neuromuscular Blocking Agents
- Remifentanil
- Propofol
- Sevoflurane
- Atracurium
Other Study ID Numbers
Other Study ID Numbers
- 2008/22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.